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Abstract
Background:  Inflammation is increasingly recognized as an important component of
tumorigenesis, although the mechanisms involved are not fully characterized. The invasive capacity
of cancers is reflected in the classic metastatic cascade: tumor (T), node (N) and metastasis (M).
However, this staging system for cancer would also have a tumoral biological significance.
Presentation of the hypothesis: To integrate the mechanisms that control the inflammatory
response in the actual staging system of cancer. It is considered that in both processes of
inflammation and cancer, three successive phenotypes are presented that represent the expression
of trophic functional systems of increasing metabolic complexity for using oxygen.
Testing the hypothesis: While a malignant tumor develops it express phenotypes that also share
the inflammatory response such as: an ischemic phenotype (anoxic-hypoxic), a leukocytic
phenotype with anaerobic glycolysis and migration, and an angiogenic phenotype with hyperactivity
of glycolytic enzymes, tumor proliferation and metastasis, and cachexia of the host. The increasing
metabolic complexity of the tumor cell to use oxygen allows for it to be released, migrate and
proliferate, thus creating structures of growing complexity.
Implication of the hypothesis: One aim of cancer gene therapy could be the induction of
oxidative phosphorylation, the last metabolic step required by inflammation in order to
differentiate the tissue that it produces.
Background
The link between inflammation and the development of
cancer has been recognized since 1863, when Rudolf Vir-
chow discovered leukocytes in neoplastic tissues and
made the first relation between inflammation and cancer
[1]. Since then, a number of cancers have been linked to
inflammatory origins [2] and in many cases it has been
considered how the tumor microenvironment highly
resembles an inflammatory site [3,4]. Nowadays, the
causal relationship between inflammation and cancer is
widely accepted.
Inflammation is increasingly recognized as an important
component of tumorigenesis, although the mechanisms
involved are not fully characterized [4-6].
Tumors can be noninvasive or benign, because they are
cured easily by simple removal, and invasive -also called
malignant or cancers that invariably kill their host if
untreated [7]. This invasive ability of cancers is reflected in
the classic metastatic cascade, which is staged according to
the volume of the primary tumor and its depth of invasion
(T stage), the number and the volume of occupied lymph
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nodes and the invasion through their capsule (N stage), as
well as the presence of distant metastases (M stage) [7].
However, a staging system for cancer should fulfill two
important characteristics: the first of these would be to
ensure a common terminology for cancer that can be
understood by clinicians in all specialities and the second
is that this system, for example, the tumor node, and
metastastis one (TNM) should be continually submitted
to critical evaluation and change when clinically indicated
[8].
One requirement for both conditions to be fulfilled
would be that the staging system would also have a
tumoral biological significance. Therefore, it should be
kept in mind that while a malignant tumor develops, it
can express phenotypes that also share the inflammatory
response.
According to Elias Zerhouni, as science grows more com-
plex, it is also converging on a set of unifying principles
that link apparently disparate diseases through common
biological pathways and therapeutic approaches [9]. Thus
research tactics and strategies may become very similar
across diseases [9,10]. In this way, to integrate the mecha-
nisms that govern the inflammatory response with the
actual staging system of cancer, could enrichen the patho-
genic knowledgement of the malignant tumor.
Presentation of the hypothesis
The successive pathophysiological mechanisms that
develop in the interstititum of tissues when they undergo
acute post-traumatic inflammation are considered
increasingly complex trophic functional systems for using
oxygen [11-13].
The nervous or immediate functional system presents
ischemia-revascularization and edema, which favor nutri-
tion by diffusion through injured tissue. This trophic
mechanism has a low energy requirement that does not
require oxygen (ischemia) or in which oxygen is not cor-
rectly used, with the subsequent development of reactive
oxigen species (reperfusion) [11,13].
The immune or intermediate functional system produces
coagulation and infiltration of the injured tissue by
inflammatory cells, especially by leukocytes. Hence,
extracelullar digestion, by enzyme release (fermentation)
and intracellular digestion by phagocytosis may be associ-
ated with a hypothetical trophic capacity of the neigh-
bouring cells. Improper use of oxygen persists in this
immune phase. Activated phagocytes would require
anaerobic glycolysis as the main source of ATP for their
functions. During this phase, lymphatic circulation plays
a major role and macrophages and dendritic cells migrate
to lymph nodes [11,13].
Finally, the endocrine functional system facilitates the
arrival of oxygen, transported by red blood cells and cap-
illaries. Angiogenesis characterizes this last phase of the
inflammatory response, and therefore nutrition mediated
by the blood capillaries is established. Oxygen and oxida-
tive metabolism are an excelent combination by which
the cells can obtain an abundant energy supply in tissue
repair by epithelial regeneration or wound healing [11-
14].
The expression of the nervous, immune and endocrine
functional systems during the inflammatory response
makes it possible to differentiate three successive phases,
which progress from ischemia, through a metabolism that
is characterized by defective oxygen use (reperfusion, oxi-
dative burst and heat hyperproduction), up to an oxida-
tive metabolism (oxidative phosphorylation) with the
correct use of oxygen that produces usable energy. Thus, it
is also tempting to speculate on whether the body repro-
duces the successive stages from which life passes from its
origin without oxygen until it develops an effective,
although costly, system for the use of oxygen every time
we suffer acute inflammation [11-13,15].
The sequence in the expression of progressively more
elaborated and complex nutritional systems could hypo-
thetically be considered the essence of the inflammation,
regardless of what its etiology or localization may be.
Hence, the incidence of harmful influences during their
evolution could involve regressing to the most primitive
trophic stages, in which nutrition by diffusion (nervous
phase) takes place. This is simpler, but also less costly and
facilitates temporary survival until a more favorable envi-
roment makes it possible to initiate more complex nutri-
tional methods (immune and endocrine phases) [11-
13,15].
If this hypothesis about inflammation is applied to tumor
development, it could be accepted that both benign and
malignant tumors also use the three functional systems,
nervous, immune and endocrine, already mentioned
above, for their evolution.
Thus, benign tumor cells seem to be able to induce the
inflammatory response in the host and collaborate in
establishing the tumor through a process called desmo-
plasia [7]. Essentially, all the elements that constitute the
inflammatory response participate in the "host reaction"
which could, therefore, have a trophic purpose for the
tumor cells [16].Molecular Cancer 2007, 6:29 http://www.molecular-cancer.com/content/6/1/29
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However, malignant tumor cells with their invasive capac-
ity, reflected in the classic metastasic cascade T-N-M [17],
seem to have the new ability to express the inflammatory
response rather than induce it in the host. In this hypo-
thetical circumstance, the successive phases that have
been described in the inflammatory response would be
expressed by malignant tumor cells and would express
their evolution with invasion and metastasis [16,18].
Testing the hypothesis
The understanding of the pathogenesis and progression of
cancer requires the establishment of the altered genetic/
metabolic factors that are essential to the development,
growth and proliferation of malignant cells [19]. This new
frontier of cancer research requires the appropiate mar-
riage of genetic/proteomic studies or the geneticist
approach with the biochemical/metabolic cellular studies
or the biochemical approach [19].
With regards to the geneticist approach, in many cancers,
a stem cell tumor model probably takes place [20]. Early
cancer stem cells derived from normal stem cells, through
a process termed "pretumor progression", or the epithelial
cancer stem cells, are susceptible to accumulate multiple
oncogenic changes that acquire the capacity for long-term
proliferation and give rise to tumors [21].
With regards to the biochemist approach, metabolic trans-
formations of malignant cells are essential to the develop-
ment and progression of all cancers [19]. Owing to the
plasticity of cancer stem cells [20-22] it should be born in
mind that while a malignant tumor develops, it can
express phenotypes that also share the inflammatory
response such as: an ischemic phenotype (hypoxic) [23]
(see Figure 1), a pro-inflammatory gene expression with
adoption of a leukocytic phenotype [5,16] and migration
to the regional lymph nodes [24] and, finally, an ang-
iogenic phenotype [25,26]. It has already been propposed
that these phenotypes represent the expression of trophic
functional systems of increasing metabolic complexity in
the inflammatory response [11-13]. Their expression by
cancer cells could have a similar significance.
In this hypothetical circumstance, malignant tumor cells,
could adopt an inflammatory-like phenotype that evolves
in three hypothetical functional phases, of increasing met-
abolic complexity, which would have also a trophic signif-
icance [16,18].
Evolutive phases of cancer cells
The three inflammatory phenotypes hypothetically
expressed by malignant tumor cells during the host inva-
sion, could help to integrate the etiopathogenic factors
that the cancer disease has. These inflammatory pheno-
types would associate the genetic factors (oncogenes,
mutations) responsible for cancer with the metabolic fac-
tors (celullar intermediary metabolism) [19].
Owing to the plasticity of cancer stem cells [27], these
could adopt an inflammatory-like phenotype that evolves
in three hypothetical functional phases with trophic sig-
nificance [16,18].
In the first or nervous phase characterized by the
ischemia-reperfusion phenomenon, the tumor cells
undergo oxidative stress, become independent and
mobile. In this phase, malignant tumor cells are nour-
ished by diffusion [16,18]. Tumor cells seem to adopt an
ischemic (anoxic-hypoxic) phenotype [23] (see Figure 1),
namely, when tumor cells come into contact with oxygen,
first they undergo a process of reoxigenation, with oxida-
tive stress and edema [18]. The hypoxic microenviron-
ment occurs very early during tumor development, when
the tumor reaches approximately 2–3 mm in diameter
[28,29]. The transcriptional response to hypoxia relies on
multi-protein complexes to regulate several transcription
factors. The most well studied mechanism identified in
this process is an interaction of a family of transcription
factors, called hypoxia-inducible factors (HIF) with a cis-
acting element, called the hypoxia-responsive element,
located in regulatory regions of target genes. The most
widely studied HIF heterodimer is HIF-1, that is the prin-
cipal regulator of the hypoxic response in most mamma-
lian cells. HIF-1 enhances the expression of hypoxia-
responsive genes and, therefore, allows improved cell sur-
vival in conditions of limited oxygen availability
[23,28,29]. Otto Warburg described in 1956 the tumor's
increased dependence upon fermentation or anaerobic
glycolysis [30]. Today, it is considered that a specific tran-
scriptional program, initiated by HIF-1, increases the
expression of glycolytic enzymes [29,31,32]. Therefore,
activation of glycolytic genes and metabolism or glyco-
lytic tumoral switch is considered a metabolic adaptation
to hypoxia through increased conversion of glucose to
pyruvic acid and, subsequently, to lactic acid [31,32].
Hypoxic tumor cells, through the glycolytic switch as the
main source of ATP, also become resistant to apoptosis,
present inhibition to differentiation and become more
likely to migrate to less hypoxic areas [33,34]. Moreover,
during these initial vascular stages of tumor growth,
which is when the tumor mass is less than 0.5 cm, nutri-
tion can be achieved by diffusion [35].
In this evolutive stage, the tumor cell could acquire motil-
ity and, therefore, an invasive ability. Malignant epithelial
cells use specific integrins to allow for survival, motility
and invasion [36]. Tumor cell spreading in this early evo-
lutive stage could involve a reorganization of the actin
cytoskeleton, that is mediated through integrin [36,37].
Malignant tumor cells utilize actin to produce a propul-Molecular Cancer 2007, 6:29 http://www.molecular-cancer.com/content/6/1/29
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sive form of movement in which highly deformable
tumor cells can travel through the tissues [37]. They do
not degrade matrix but instead, go around matrix barriers
and squeeze through narrow spaces by ameboid migra-
tion [36,38].
The progressive formation of reactive oxygen species
(ROS) secondary to gradual oxigenation of the tumor cell
would increase its oxidative and nitrosative ability. In this
hypothetical situation, oxidative stress could favor a more
aggressive type of host invasion [11]. As a result, during
the earlier phase of tumor progression, the metabolic
autonomy and invasive capacity of the tumor cell would
induce their premature migration to the peripheral tissue
[16]. Malignant cells are able to remain "dormant" but
viable for some period of time after the host invasion [39].
It has been proposed that tumor dormancy may be due to
preangiogenic micrometastasis which subsequently
acquires the ability to become vascularized [35,40].
In the second or immune phase, tumor cells could pro-
duce coagulation and express a leukocytic phenotype with
Using by the malignant tumor cell of the mechanisms involved in the inflammatory response Figure 1
Using by the malignant tumor cell of the mechanisms involved in the inflammatory response. a : Ischemicphenotype. Oxida-
tive stress is produced from the anoxia until the beginning of the oxygenation (hypoxia) and the tumor cell becomes independ-
ent (autocrine) and acquires motility. In this phase nutrition by diffusion stands out. b: Leukocytic phenotype. A provisional 
matrix is developed by hypercoagulation. The hyperproduction of enzymes, chemokines and cytokines induce the lymphatic 
migration (paracrine), as well as the uptake of nutrients by the cancer cell. c : Angiogenic phenotype. Angiogenesis makes it 
possible that a number of host substances, including hormones (endocrine) would be used by the tumor cell in its own metab-
olism. This fact favor its excessive growth and the metabolic manipulation of the host inducing cachexia. SC: Stem cell; SHC: 
Stem hematopoietic cell; P: plasma; Pt: Platelets. PMN: Polimorphonuclear neutrophils; MN: Monocite; L: Limphocyte; RBC: 
red blood cells; TC: Tumor cell; ep: epithelial cell ; N: node; T: Tumor, M: Metastasis.Molecular Cancer 2007, 6:29 http://www.molecular-cancer.com/content/6/1/29
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anaerobic glycolysis as the main source of ATP. This phe-
notype permits tumor cells to develop adhesive interac-
tions with the surrounding matrix and cells, lymphatic
migration and invasion of the host lymph nodes [16,18].
Hypercoagulation in cancer patients is another factor for
tumor progression. Although the mechanism behind
hypercoagulation in cancer patients is unclear, the main
factor responsible for hypercoagulation has been consid-
ered to be cancer itself, by producing and secreting proco-
agulant substances accompanied by decreasing of
coagulation inhibitors [41]. By hypercoagulation, cancer
cells acquire a provisional matrix that favors both their
survival and invasion [11,14].
Tumor cells with leukocytic phenotype can overexpress
matrix metalloproteinases (MMPs). In many instances,
therefore, the extensive alterations produced by MMPs in
the stromal microenvironment of epithelial cancer stem
cells promote tumor progression [21]. They travel more
slowly than cells using ameboid migration but are more
destructive [36]. However, tumoral cell nutrition could be
mediated by this great extracellular digestive potential. In
this hypothetical situation, the degradation of the sur-
rounding matrix by proteases would favor nurishing the
tumoral cell and, therefore, its ability to proliferate and
invade. Aggressive epithelial cancer cells using this mech-
anism of invasión or "mesenchymal-like mechanism" are
regarded as having undergone dedifferentiation through a
process called epithelial-mesenchymal transition (EMT)
[36,42].
Reoxigenation of hypoxic tumor cells may cause reper-
fusion injury with oxidative and nitrosative stress, like
what occurs in the inflammatory response by the genera-
tion of ROS and nitrogen reactive species [43]. In most
inflammatory responses, the actions of ROS are mediated
by the IκB/nuclear factor (NF)-κB system and, this system,
in turn, can be regulated by hypoxia and/or reoxygenation
[23]. More specifically, the expression of inducible genes
leading to the synthesis of cytokines, chemokines,
cytokine and chemokine receptors, adhesion molecules
and autacoids relies on transcription factors, and among
the primary transcription factors, NF-κB plays a main role
in the regulation of inflammatory mediators [44].
The activation of general stress-responsive transcription
factors, such as NF-κB, in tumor cells [45-47], could imply
their complete transition to a hypothetical phase called an
immune phase, since this could be associated with pro-
inflammatory gene expression. Hence, tumor cells may
co-opt key mechanisms by which inflammation interfaces
with cancer, to further their colonization of the host it
[16,18]. Hence, the activation of NF-κB in carcinoma cells
results in elevated expression of cell-cycle genes, such as
cyclin D1, inhibitors of apoptosis, and proteases that pro-
mote invasión [47].
The hypothetical activation of the leukocytic phenotype
in malignant tumor cells would permit these cells to fulfill
functions characteristic of activated inflammatory cells
(see Figure 1). For example, functions associated with
neutrophils like the hyperproduction of extracellular pro-
teases, such as MMPs and other protease enzymes that
carry out a true extracellular digestion of the basement
membrane and the extracellular matrix, also aid in inva-
siveness in the early stages of the disease [48,49]. Cancer
cells can present pseudopodia formation and directional
migration as well [36,42,50].
Other functions seem to correspond to a monocyte-mac-
rophage phenotype, in the sense that tumor cells migrate
to the regional lymph nodes through lymphatic capillar-
ies [51]. It has been suggested that malignant cells may
adopt normal mechanisms of lymph node homing during
metastasis [24]. The adoption of an immune phenotype
by cancerous cells is associated with the formation of new
lymphatic vessels [41,51].
During the immune phase of tumor progression, soluble
factors could push tumor cells towards a monocyte-like
phenotype and induce their premature migration to
peripheral tissue. Hence, the monocyte phenotype of the
tumor cells would favor the homing of metastatic tumor
cells to specific organs, specially those where populations
of resident macrophages are abundant, i.e. lung (alveolar
macrophages), liver (Kuppfer cells), brain (microglia) and
bone (osteoclasts) [16]. Cancer cells may also secrete fac-
tors that cause bone marrow-derived hematopoietic pro-
genitor cells to migrate to premetastatic sites [52].
Therefore, a premetastatic "trophic" niche may be formed
by bone marrow-derived hematopoietic cells that attract
tumor cells and support a devoloping metastasis [52-54].
Besides, cells with stem cell features have been identified
neither in tumors nor in metastatic lesions [55]. There-
fore, cells with different grades of dedifferentiation from
stem cells to bone-marrow-derived hematopoietic cells
seem be involved in the metastatic colonization [53].
Particularly, disseminated tumor cells in bone marrow
can be detected in 20–40% of cancer patients without any
clinical or histopathological signs of metastasis [56]. The
particular bone marrow environment may allow these
cells to survive and disseminate later into other distant
organs. This "dormant stage" of disseminated tumor cells
may explain why these cells are relatively resistant to
chemotherapy [57].
Primary tumors and metastasis exhibit a similarity of
matched upon gene expression profiling. However, theMolecular Cancer 2007, 6:29 http://www.molecular-cancer.com/content/6/1/29
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inflammatory mechanisms involved in the metastatic col-
onization could be considered organ-specific [52,53].
Cancer stem cells can also exhibit a lymphocytic pheno-
type. It has been suggested that an aberration in the apop-
tosis process leads to formation of the cancer stem cell
from autoreactive T cells. Therefore, the resultant cancer
stem cell still preserves some effector T cell functions, such
as homing into sites of inflammation [22]. Through this
hypothetic lymphocytic phenotype, the cancer cell could
direct the metastatic colonization. With some similarity to
lymphocytes [58], the tumor cell, having suffered primary
activation, can migrate to effector specific sites (lung,
liver) where they may adopt distinct functional proper-
ties. Thus, the metastatic colonization could be inter-
preted as an attempt of the tumor cell to carry out
organogenesis, but due to an insufficient metabolic activ-
ity of metastastic tumor cells, this would fail.
The hypothetical adoption of an immune phenotype by
the tumor cells would also imply the acquisition of a sim-
ilar metabolism. In this situation, like the activated
phagocytes (granulocytes, monocytes), their functions
would require anaerobic glycolysis as the main source of
ATP [59,60]. In this sense, it was shown that HIF-1α is
essential for the upregulation of enzymes of the glycolytic
pathway to supply phagocytes with sufficient levels of ATP
[59]. Tumor cells express HIF-1α and upregulate glycoly-
sis through the activation of the energy-sensing enzyme
AMP-activated protein kinase (AMPk) [31,32,61]. AMP
levels rise as the cellular ATP: ATP ratio declines. This rise
in AMP activates AMPk [62]. Activated AMPk facilitates
the "glycolytic switch", and provides a substrate-depend-
ent growth advantage to malignant tumors [34].
As a result, in this second or immune phase, the tumor cell
could express a leukocytic phenotype with anaerobic gly-
colysis as the main source of ATP, which permits the inva-
sion of the host by both lymphatic migration (by lymph
vessels and nodes) and hematic migration (micrometas-
tases or preanagiogenic metastasis) [16,18].
The adoption of an immune phenotype by cancerous cells
is associated with the formation of new lymphatic vessels
[51]. Lymphangiogenesis is not only crucial for cancer
cells to metastasize to the regional lymph nodes, but also
offer the tumor the possibility to disseminate pro-inflam-
matory mediators in the host, which would produce a sys-
temic inflammatory response syndrome (SIRS) [63]. SIRS,
mediated in part by pro-inflammatory cytokines, plays a
role in the genesis of cachexia, associated with both criti-
cal illness and chronic inflammatory diseases [64]. These
cytokines are further thought to induce an acute phase
protein response (ARP) and produce the alterations in the
metabolism of lipids, proteins and carbohydrates identi-
fied as crucial markers of acute inflammation in states of
malignancy and critical illness [63,64].
Finally, in a third or endocrine phase, it has been pro-
posed that the tumor cell can be nourished by capillaries,
which are present due to angiogenesis. In this phase, the
tumor cell also acquires the capacity to proliferate and
cause cachexia in the host [16,18]. Angiogenesis charac-
terizes this last phase of cancer evolution and permits
numerous substances, including hormones, to be trans-
ported by the blood (see Figure 1). For this reason the
term "endocrine" seems appropiate for this evolutive
phase.
Angiogenesis requires migration of endothelial cells into
the intersticial space with the subsequent proliferation
and differentiation into capillaries [18]. Tumors induce
angiogenesis by activating tumor stroma cells, by releas-
ing angiogenic factors from the extracellular matrix to
which they bind by the emergence of new epitopes in the
extracellular matrix that promotes angiogenesis, and via
the switching of neoplastic cells to an angiogenic pheno-
type [26,65,66]. However, tumor-angiogenesis produce a
tumor-associated vasculature that is chaotic, both in struc-
ture and function. These characteristics impair tumor
blood flow and delivery of oxygen [26], but they favor its
growth since without angiogenesis tumors rarely grows
larger than 2 to 3 mm [65].
Hypoxia inducible factors drive the transcription of spe-
cific genes that promote tumor angiogenesis and systemic
erythropoiesis [61]. Host tumors, which have grown
larger than 1 mm3 contain regions of low oxygen tension
(hypoxia), making the formation of new blood vessels, or
neoangiogenesis, essential for further tumor growth [66].
Tumor survival and metastasis are controlled by the bal-
ance between angiogenesis stimulators and inhibitors
[50]. Among the angiogenic signals, vascular endothelial
growth factor (VEGF) stands out [67,68]. VEGF also
increases vascular permeability and stimulates the mobili-
zation of endothelial progenitor cells [41,53]. HIF-1α
mediates the expression of angiogenic proteins, and
among them, VEGF is probably the most potent one
[69,70]. In addition to upregulating angiogenesis, how-
ever, HIF-1 directly contributes to the downregulation of
the oxidative phosphorylation and upregulation of glu-
cose uptake and glycolytic enzyme expression [32,69,71].
The appearance of both local (tumor or T stage) and sys-
temic (metastasis or M stage) angiogenesis would provide
the tumor substances produced by the host, particularly
hormones and growth factors, via the blood. This exoge-
nous contribution, which the tumor cannot synthesize,
could favor the expression and activity of glycolyticMolecular Cancer 2007, 6:29 http://www.molecular-cancer.com/content/6/1/29
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enzymes [32]. Initial studies found that a variety of onco-
genes and growth factors could increase the expression of
glycolytic enzymes [72]. Subsequently, the increased met-
abolic ability would increase the production of ATP,
which would be used mainly for proliferation. Therefore,
it is in this evolutive phase when cancer can be considered
a growing disease [16,18].
The cancer cachexia syndrome, characterized by anorexia,
weight loss with muscle wasting and increased energy
expenditure [73-75], could be the result of an effective
metabolic functional ability that the cancer cell develops
to use the only available storage of substrates, those
belonging to the host [18]. Hence, the mobilization of
substrates that the SIRS produce in the host, through the
alteration of the carbohydrate, lipid and protein metabo-
lism with hypermetabolism, would favor its use by the
cancer cell [76]. For this reason, it could be considered
that in advanced stages of the cancerous disease, tumor
cells acquire the ability to metabolically manipulate the
host in order to benefit their own development [18].
Consequently, it could be considered that the successive
phases of tumor evolution could have a trophic meaning,
although the pathophysiological mechanisms involved
would increase in complexity [16,18]. This hypothetical
approach to the mechanism that governs tumoral evolu-
tion could be based on the increasingly metabolic capac-
ity of the tumor cell to use oxygen over the successive
phases of release, migration, and proliferation [77].
Implication of the hypothesis
Since the phases of tumoral evolution, like the phases
described of post-traumatic inflammation [11,13,14], go
from ischemia to a progressive oxigenation, it is also
tempting to speculate on whether the tumor cell repro-
duces some of the successive stages by which life passes
from its origin without oxygen until it develops an effec-
tive, although costly, system for the use of oxygen [78,79].
If so, the successive metabolic switches that cancer under-
goes allows it to acquire a growing ability, both to invade
the host and use the host sources of substrates until its
metabolic reserves are all used up [77].
The hypothesis that atmospheric oxygen concentrations
affected the timing of the evolution of cellular compart-
mentalization by constraining the size of domains neces-
sary for communications across membranes has been
suggested [80]. Thus, the relatively rapid changes in the
size of the oxygen-rich external domains coincide with
increasingly organism complexity. This points towards a
key role for oxygen in the increase in abundance and size
of receptors over time [80] and adds to a growing body of
literature connecting atmospheric oxygen levels with mac-
roevolutionary changes, most recently with complexity in
metabolic networks and cell types [78-80]. Therefore, a
correlation between the increased organism complexity
and the development of the use of the atmospheric oxy-
gen could be established [79-81].
This correlation also seems to exist in the development
and proliferation of malignant cells. Thus, it has been pro-
posed that if cancer evolves in these three successive
phases [16,18], progressive cellular complexity would
occur parallel to a gradual oxygenation process. In this
hypothetical situation, successive metabolic switches
would be activated by tumor cells. Thus, an initial anoxic
metabolism is gradually replaced by progressively more
complex metabolisms characterized by a growing capacity
to use oxygen [80].
Hence, during the first or nervous phase, the absence of
(anaerobic phenotype) or low (reoxygenation pheno-
type) oxygen availability of the cancer cell is coupled with
a decreased metabolic activity, low energy requirement
and nutrition by diffusion. In this early stage, the tumor
cell ha few surface membrane receptors, which in turn
increase cancer cell autonomy and favors the autocrine
function.
During the immune phase, cancerous cells acquire a leu-
kocytic phenotype. The increased metabolic activity, asso-
ciated with a greater use of oxygen, would favor the
enzymatic digestive ability as well as an increased capacity
for the intercellular or paracrine relation. Cancer cell
derived paracrine signals may induce intercellular path-
ways that promote their leukocytic behavior with lym-
phatic migration and metastatic growth in lymph nodes.
In the last or endocrine phase, the tumor cell induces an
angiogenic phenotype. The most primitive angiogenic
tumor phenotype could be vasculogenic mimicry [82] or
the novo generation of blood vessels, without the partici-
pation of endothelial cells. [82,83]. For this process,
tumor cells acquire characteristics similar to endothelial
cells, namely, they would be able to inhibit the above
expressed leukocytic tumor phenotype (antioxidant and
antienzimatic) and induce the abundant expression of
adhesion molecules. This fact makes up an important
component of the molecular switch to vasculogenic mim-
icry [84,85] to form a vascular-like tube formation
[82,83,85]. Through this means, tumor cells contribute to
conducting blood in vascular-like structures, a process
that would be independent of regular angiogenesis
[82,83,85].
By either vasculogenic mimicry [82,83] or by angiogenesis
[53,65,68] the angiogenic switch promotes the endocrine
function of the malignant tumor. In this phase, the cancer
cell, through the angiogenic switch (endocrine), would beMolecular Cancer 2007, 6:29 http://www.molecular-cancer.com/content/6/1/29
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able to establish a metabolic activity in synergy with the
host. Tumors, when vascularized, use substances, like
neurotransmitters and hormones, synthesized by the host
due to its (the host) correct functioning of oxidative phos-
phorylation [80]. These substances in turn could enhance
the glycolytic activity of the tumor [30-32]. Therefore, the
metabolic limit of the tumor in this evolutive phase is pre-
vented by the additional contribution of mediators sup-
ported by the aerobic metabolism of the host.
As cancer cells develop mechanisms to create their vascu-
larisation, their metabolic demands could increase, partic-
ularly those related with their excessive potential to
proliferate, which finally cause a cachectic state in the host
[73-75,86]. The malignant tumor thus causes a profound
alteration in the metablolism of the host, adapting it for
its own benefit. Thus, it increases oxidative stress, elevates
resting energy metabolism, increases proteolysis with lean
body mass wasting, enhances lipid mobilization and
increases liver gluconeogenesis. In particular, neogluco-
genesis allows the tumor cells a high contribution of its
favorite substrate, that is glucose, for the anaerobic metab-
olism. [74,75,86].
During these evolutive phases, it could be considered that
progressive metabolic tumor complexity is associated
with a growing structural complexity. In particular, the use
of the pathophysiological mechanisms of the inflamma-
tory response to invade and take over the host would pro-
vide a considerable advantage for its development. In an
attempt to create a increasingly more complex structure,
the tumor cell is isolated from the neighbouring cells; it
becomes autonomous (nervous phase), migrates
(immune phase) and proliferates (endocrine phase)
[16,18]. It could be speculated that due to the use of both,
the tumor cell and the inflammatory response, of the
same described basic mechanisms, they would also share
the same objective, namely, the creation of new tissue.
This neoforming capacity can be local (cicatrization),
regional (regeneration) or systemic (embryogenesis) [13].
However, the cancerous cell is not able to reach the last
basic mechanism that defines the inflammatory response,
which is differentiation [12-14]. Perhaps, this functional
incapacity of the malignant tumor cell is associated with
the impossibility of expressing an efficient oxidative
metabolism (oxidative phosphorylation) to obtain the
large amount of energy that this specialized cell function
requires. Due to this metabolic and functional limitation,
the cancerous cell, although it recognizes potential targets
of development during metastasis, is not able to differen-
tiate.
The demonstration that the growth of tumors and metas-
tasis are dependent on the development of their vascular
supply [25,53,65-68,70] supports the idea that antiangio-
nesis has been regarded as a target for cancer therapy
[67,68,87,88].
However, a hypothetical therapeutic alternative would be
to promote its transition from this stage of maximum
aggressiveness, in which proliferation induced by angio-
genesis predominates, to a more metabolically advanced
stage that would induce its specialization. This last "step,"
which is normal in the post-traumatic inflammatory
response [11-13], however, seems to be forbidden the
cancerous cell. Perhaps, this limitation of the cancerous
cell to become specialized, when it co-opts the inflamma-
tory mechanisms of the host, is one of the main reasons
why tumors are considered "wounds that do not heal"
[89]. Hence, this would explain why the cancerous cell
recognizes the chronic inflammatory processes to be the
right environment for its development. [49,90]. In this
hypothetical situation, the induction by gene therapy of
the tumor cell specialization could be an alternative can-
cer therapeutic strategy. In essence, perhaps we only have
to help the cell finish a process that was already initiated
when metastatic colonization took place [53].
Conclusion
The need to establish a link between the evolutive stages
of cancer (TNM) and its biological significance, could be
of interest for integrating the pathophysiological mecha-
nisms that control this disease.
It has been hypothesized that while the malignant tumor
develops, it can express phenotypes that also share the
inflammatory response. These phenotypes can represent
the expression of trophic functional systems of increasing
metabolic complexity for using oxygen. Using the mecha-
nisms characteristics of the inflammatory response, the
tumor cell evolves through its release, migration and pro-
liferation. The incapacity of tumor cell to successfully
complete the last phase of the inflammatory response,
namely, specialization, allows for considering new thera-
peutic alternatives based on its destruction.
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